Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Batimastat (BB-94): From MMPs to Assay Design
2026-10-01
Batimastat (BB-94) is a broad-spectrum hydroxamate MMP inhibitor with applications spanning mechanistic proteolysis studies, neuromuscular-junction assays, and cancer models. This guide develops a causal assay framework that separates MMP activity, BDNF processing, cellular phenotype, and translational interpretation.
-
ATM Inhibition and Fenofibrate in HGSOC
2026-10-01
This study identifies a metabolic vulnerability created by ATM inhibition in high-grade serous ovarian cancer cells and shows that combining ATM blockade with fenofibrate produces synergistic growth suppression through cellular senescence. Its main contribution is a data-guided strategy for extending DNA damage response inhibitor research beyond conventional combinations with DNA-damaging agents.
-
EZ Cap™ Human p53 mRNA (ψUTP) Research Guide
2026-09-30
Explore how EZ Cap™ Human p53 mRNA (ψUTP) enables controlled, transient p53 perturbation for oncology assays. This guide connects modified-mRNA biology with lipid nanoparticle delivery decisions, assay controls, and translational limitations.
-
Tetraethylammonium Chloride: Assay Logic
2026-09-29
Tetraethylammonium chloride and TEAC are examined here as mechanistic tools for separating potassium-channel pore blockade from downstream cellular effects. This guide connects ion-conduction assays, vascular research, and the Jonas et al. electrophysiology framework while emphasizing controls, interpretation, and translational limits.
-
Bay 11-7085: NF-κB Workflow Guide
2026-09-29
Build a controlled NF-κB perturbation workflow with Bay 11-7085, from TNFα-stimulated cell assays to disease-relevant models of endometriosis and meningitis. The guide emphasizes pathway timing, apoptosis and viability controls, formulation quality, and the limits of interpreting a chemical probe as proof of mechanism.
-
Anti Reverse Cap Analog for High-Output mRNA
2026-09-28
Learn how orientation-specific capping with ARCA can improve synthetic mRNA translation, reproducibility, and assay design. The workflow also shows how capped mRNA can support time-controlled studies of TCAIM–OGDH mitochondrial regulation without overstating what the reference study proves.
-
Norovirus Co-opts NINJ1 for Selective NS1 Secretion
2026-09-28
Song et al. show that murine norovirus uses caspase-3 processing and the host membrane-rupture protein NINJ1 to release viral NS1, revealing selectivity within a process previously associated with bulk cellular protein release. The findings connect viral protein secretion to regulated cell death and identify experimental questions about cargo recognition, infection models, and the interpretation of extracellular proteins.
-
Methylprednisolone in Osteonecrosis Research
2026-09-27
Use Methylprednisolone as a defined glucocorticoid challenge to connect inflammation, osteoclast activity, and femoral-head injury—not as a bone-protective treatment. This workflow pairs model induction with cytokine assays, micro-CT, histology, and pathway readouts, while separating published animal conditions from proposed assay-optimization steps.
-
Batimastat (BB-94): MMP Inhibition and Research Use
2026-09-26
Batimastat (BB-94) is a broad-spectrum hydroxamate inhibitor reported to inhibit several matrix metalloproteinases at nanomolar concentrations. Its product data support cancer-model research, while any application to BDNF processing or neuromuscular-junction development remains a testable hypothesis rather than a demonstrated result.
-
Protease Inhibitor Cocktail EDTA-Free: Practical Use
2026-09-25
This EDTA-free cocktail helps limit endogenous proteolysis during protein extraction and sample preparation, including workflows where divalent cations need to remain available. Use it for protein-preservation workflows such as immunoblotting or co-immunoprecipitation, but not when the assay depends on measuring active protease function; compatibility should be checked for each downstream assay.
-
AG-126: Practical ERK Signaling Workflows
2026-09-25
Use AG-126 to probe ERK1/2 phosphorylation and stimulus-linked cytokine responses, with a workflow that separates product-supported evidence from exploratory neuroscience questions. Practical dose-ranging, vehicle controls, assay timing, and troubleshooting help researchers interpret this micromolar inhibitor more rigorously.
-
GST-Driven Lambda-Cyhalothrin Resistance in Thrips
2026-09-24
A 2024 study links glutathione S-transferase activity to lambda-cyhalothrin resistance in Megalurothrips usitatus, identifying MuGSTs1 as a strongly responsive gene and connecting GST inhibition with weaker antioxidant defenses. The findings support a functional role for redox protection in insecticide tolerance, while also highlighting the need to distinguish GST-specific effects from the broader actions of chemical inhibitors.
-
SMPD4, Ceramide, and Primary Cilia in Brain Development
2026-09-24
A 2024 Development study links SMPD4-dependent ceramide production to primary-cilium integrity and neural cell survival, offering a mechanistic framework for microcephaly and cerebellar hypoplasia. By combining a mouse loss-of-function model with human SMPD4-deficient induced pluripotent stem cells and ceramide rescue, the work connects sphingolipid metabolism to brain development while leaving important questions about tissue-specific mechanisms open.
-
Batimastat (BB-94): MMP Assays and Research Workflows
2026-09-23
Use Batimastat (BB-94) to test how broad-spectrum MMP activity contributes to matrix remodeling, tumor behavior, and—cautiously—extracellular BDNF processing. This guide pairs evidence-based cancer applications with a practical, clearly bounded workflow for exploring proteolysis in early neuromuscular-junction development.
-
AZD0156: Rethinking ATM Inhibition in Translation
2026-09-23
A translational framework for using AZD0156 as a selective ATM kinase inhibitor, connecting DNA damage biology, pharmacologic validation, assay design, and cancer therapy research strategy.